SEHK:2228Life Sciences
XtalPi Biopharma GPCR Pact Tests AI Drug Discovery And Revenue Potential
XtalPi Holdings (SEHK:2228) has entered a new partnership with a major international biopharma company to develop oral small molecule drugs targeting a complex GPCR.
The collaboration uses XtalPi's AI and quantum physics platforms, combined with automated labs, to work on challenging GPCR targets.
The deal carries a potential value of more than US$400 million, reflecting meaningful commercial scope for XtalPi's technology.
XtalPi Holdings trades at HK$7.04, with the share price down 6.0%...